{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:13:56Z","timestamp":1791486836698,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004192","name":"National Science and Technology Development Agency","doi-asserted-by":"publisher","award":["P1650727"],"award-info":[{"award-number":["P1650727"]}],"id":[{"id":"10.13039\/501100004192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["BRF1-029\/2565"],"award-info":[{"award-number":["BRF1-029\/2565"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021186","name":"Office of National Higher Education Science Research and Innovation Policy Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115691","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:47:45Z","timestamp":1697262465000},"page":"115691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma"],"prefix":"10.1016","volume":"168","author":[{"given":"Pornpimon","family":"Yuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-9948","authenticated-orcid":false,"given":"Nunghathai","family":"Sawasdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krissada","family":"Natungnuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punchita","family":"Rujirachaivej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piriya","family":"Luangwattananun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-8031","authenticated-orcid":false,"given":"Jatuporn","family":"Sujjitjoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-5927","authenticated-orcid":false,"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.biopha.2023.115691_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib2","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.biopha.2023.115691_bib3","first-page":"1","article-title":"Newly diagnosed myeloma in 2020","volume":"40","author":"Moreau","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"16","key":"10.1016\/j.biopha.2023.115691_bib4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl. J. Med"},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl. J. Med"},{"issue":"6","key":"10.1016\/j.biopha.2023.115691_bib6","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.biopha.2023.115691_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"18","key":"10.1016\/j.biopha.2023.115691_bib8","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2023.115691_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115691_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","article-title":"The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed","volume":"22","author":"Laabi","year":"1994","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.biopha.2023.115691_bib11","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12885-023-10591-1","article-title":"The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma","volume":"23","author":"Xu","year":"2023","journal-title":"BMC Cancer"},{"issue":"25","key":"10.1016\/j.biopha.2023.115691_bib13","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115691_bib14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115691_bib15","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin's lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2023.115691_bib16","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00262-020-02838-8","article-title":"CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors","volume":"70","author":"Chen","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.biopha.2023.115691_bib17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115691_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric antigen receptor T cells targeting integrin alphavbeta6 expressed on cholangiocarcinoma cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib19","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41598-021-85747-9","article-title":"Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma","volume":"11","author":"Supimon","year":"2021","journal-title":"Sci. Rep."},{"issue":"Pt B","key":"10.1016\/j.biopha.2023.115691_bib20","article-title":"Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells","volume":"89","author":"Sangsuwannukul","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2023.115691_bib21","first-page":"11","article-title":"Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains","author":"Wutti-in","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115691_bib22","article-title":"Clinical experience of CAR T cells for multiple myeloma","volume":"34","author":"Simmons","year":"2021","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115691_bib23","first-page":"12","article-title":"PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma","author":"Tamura","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-018-0589-1","article-title":"Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1\/PD-L1 pathway","volume":"11","author":"Tremblay-LeMay","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115691_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib26","doi-asserted-by":"crossref","first-page":"12641","DOI":"10.1038\/s41598-020-69616-5","article-title":"PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model","volume":"10","author":"Lee","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12943-022-01669-8","article-title":"Tumor buster - where will the CAR-T cell therapy 'missile' go?","volume":"21","author":"Qu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"Pt B","key":"10.1016\/j.biopha.2023.115691_bib28","article-title":"Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition","volume":"113","author":"Yuti","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115691_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI multiple myeloma steering committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2023.115691_bib31","first-page":"119","article-title":"CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.biopha.2023.115691_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of humanized Anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.115691_bib33","article-title":"Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: an urgent unmet need","author":"Martin","year":"2023","journal-title":"Blood Rev."},{"key":"10.1016\/j.biopha.2023.115691_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101459","article-title":"Resistance against anti-CD19 and anti-BCMA CAR T cells: recent advances and coping strategies","volume":"22","author":"Atilla","year":"2022","journal-title":"Transl. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115691_bib35","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s40001-022-00923-5","article-title":"PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed\/refractory multiple myeloma patients","volume":"27","author":"Chen","year":"2022","journal-title":"Eur. J. Med Res"},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.biopha.2023.115691_bib38","doi-asserted-by":"crossref","first-page":"E2480","DOI":"10.1073\/pnas.1305394110","article-title":"Strength of PD-1 signaling differentially affects T-cell effector functions","volume":"110","author":"Wei","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.biopha.2023.115691_bib39","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2023.115691_bib40","article-title":"Extracellular domains of CAR reprogram T-cell metabolism without antigen stimulation","author":"Lakhani","year":"2023","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib41","doi-asserted-by":"crossref","first-page":"1943180","DOI":"10.1080\/2162402X.2021.1943180","article-title":"PD-L1\/LAG-3 bispecific antibody enhances tumor-specific immunity","volume":"10","author":"Jiang","year":"2021","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.biopha.2023.115691_bib42","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.biopha.2023.115691_bib43","doi-asserted-by":"crossref","first-page":"8045161","DOI":"10.1155\/2017\/8045161","article-title":"The distribution of activation markers and selectins on peripheral T lymphocytes in preeclampsia","volume":"2017","author":"Bajnok","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.biopha.2023.115691_bib44","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3389\/fonc.2020.01243","article-title":"CAR T-cells in multiple myeloma: state of the art and future directions","volume":"10","author":"Rodriguez-Lobato","year":"2020","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115691_bib45","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol. Cell Biol."},{"issue":"9","key":"10.1016\/j.biopha.2023.115691_bib46","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115691_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13058-022-01531-1","article-title":"Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC","volume":"24","author":"Harrasser","year":"2022","journal-title":"Breast Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2023.115691_bib48","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.biopha.2023.115691_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044197","article-title":"4-1BB-based CAR T cells effectively reverse exhaustion and enhance the anti-tumor immune response through autocrine PD-L1 scFv antibody","volume":"24","author":"Cheng","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223014890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223014890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:27:19Z","timestamp":1779917239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223014890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":49,"alternative-id":["S0753332223014890"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115691","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115691"}}